The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

Trial Profile

The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2013

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms REBBeCA
  • Most Recent Events

    • 10 Aug 2011 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
    • 10 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Planned end date changed from 1 Jul 2010 to 1 Jul 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top